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Abstract
Purpose—To provide patients and physicians with population-based estimates of mortality from
prostate cancer or other causes depending upon the primary treatment modality, stratified by
patient age, tumor stage and grade.
Methods—We conducted a 10-year competing-risk analysis of 45,440 men diagnosed with
clinically localized (T1 or T2) prostate cancer in California during 1995–1998. Information on
patient characteristics, primary treatment and cause of death was obtained from the California
Cancer Registry.
Results—In this population-based cohort, the most common primary treatment was surgery
(40.4%), followed by radiotherapy (29.1%), conservative management (20.8%), and androgen
deprivation therapy (ADT) monotherapy (9.8%). Prostate cancer mortality differed significantly (p
< 0.0001) across treatment groups among patients <80 years at diagnosis with moderately or
poorly differentiated disease; the 10-year disease-specific mortality rates were generally highest
for men treated with ADT monotherapy [range: 3.3% (95% CI=0.8–12.5%) to 53.8% (95%
CI=34.4–72.2%)], intermediate for men treated with conservative management [range: 1.7% (95%
CI=0.7–4.6%) to 30.0% (95% CI=16.2–48.8%] or radiotherapy [range: 3.2% (95% CI=1.8–5.5%)
to 18.3% (95% CI=15.1–22.0%)], and lowest for men treated with surgery [range: 1.2% (95%
CI=0.8–1.7%) to 11.0% (95% CI=8.4–14.2%)].
Conclusion—The cause-specific mortality estimates provided by this observational study can
help patients and physicians better understand the expected long-term outcomes of localized
prostate cancer given the initial treatment choice and practice patterns in the general population.
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Over the past two decades, widespread application of prostate specific antigen (PSA) testing
has shifted the clinical landscape of prostate cancer to earlier stages of the disease.[1] In
2012, over 241,000 U.S. men were diagnosed with prostate cancer, approximately 80% of
whom had localized (stage T1 or T2) disease.[2] To date, randomized trials have shown
little survival benefit with PSA testing, indicating that many indolent tumors are being
overdetected and overtreated.[3,4] The optimal treatment of localized prostate cancer
remains controversial.[5] Standard treatment options include surgery, radiation, and
conservative management (active surveillance or watchful waiting).[6] Additionally,
primary treatment with androgen deprivation therapy (ADT) is frequent despite lack of
evidence from clinical trials to support its use as monotherapy for localized prostate cancer.
[7]
Randomized controlled trials are currently underway that will ultimately help determine
whether or not treatment reduces mortality in men with localized prostate cancer.
Observational studies have suggested that active surveillance of low-risk patients may be a
safe alternative to initial treatment and may preserve quality of life.[8] However, recent
results from randomized trials of radical prostatectomy compared with observation
demonstrated that surgery significantly reduced prostate cancer mortality among men
younger than 65 years at diagnosis[9] or high-risk disease,[10] indicating that some patient
subgroups may have a survival benefit from aggressive treatment.
The natural history of prostate cancer is heterogeneous, and most men with localized
prostate cancer will die of causes other than their disease.[11] Therefore, knowledge of a
man’s absolute risks of dying from prostate cancer versus other causes is critical for making
informed treatment choices. We assembled a population-based cohort of 45,440 men
representing virtually all men diagnosed with clinically localized prostate cancer in
California during 1995–1998. Our aim was to describe the absolute 10-year mortality from
prostate cancer or competing causes of death in patient populations initially treated with
surgery, radiation, ADT monotherapy or conservative management.
PATIENTS AND METHODS
Study population
We identified all men diagnosed with a first primary invasive adenocarcinoma of the
prostate (International Classification of Diseases for Oncology, 3rd edition [ICD-O-3] site
code 61.9; morphology code 8140) in California between January 1, 1995 and December
31,1998 using data from the California Cancer Registry (CCR; http://www.ccrcal.org/),
which captures 99% of cancer diagnoses state-wide. We chose the years 1995–1998 in order
to obtain at least 10 years of follow-up, needed because of low disease-specific mortality
among men with localized prostate cancer, and to represent the period following the
introduction of PSA testing, when stage migration had largely stabilized.[12] Eligible
patients were diagnosed with clinical stage T1 or T2 disease (N=55,082). Exclusion criteria
included: ambiguous stage (“localized, not otherwise specified”; N=5111); diagnosis on
autopsy or death certificate only (N=46); “unknown” or “other” race (N=1799); unknown
tumor grade (N=1097); lost to follow-up within 10 years (N=1119); invalid follow-up dates
(N=1); and cause of death unavailable or unknown (N=358). We also excluded cases who
received chemotherapy (N=111) within 4 months of diagnosis because chemotherapy is not
standard treatment for localized prostate cancer and could reflect more advanced disease.
The final study population consisted of 45,440 men. This study was approved by the
Institutional Review Board of the Cancer Prevention Institute of California.
Sieh et al. Page 2














The CCR regularly updates vital status information through hospital follow-up and linkages
with state and national databases and agencies. Follow-up information was available through
May 31, 2010; the median follow-up period was 138 months after diagnosis. Cases were
classified as alive or deceased within 10 years of diagnosis. The cause of death was
classified as prostate cancer or other competing causes based upon the underlying cause of
death on the death certificate, which has been shown to be a reliable means of ascertaining
death due to prostate cancer.[13,14]
Patient characteristics
Patient diagnoses and demographic data are routinely collected by the CCR in accordance
with guidelines of the National Cancer Institute (NCI) Surveillance, Epidemiology and End
Results (SEER; http://seer.cancer.gov/) program and the California Department of Public
Health. For this study, age at diagnosis was categorized in 10-year groups (<50, 50–59, 60–
69, 70–79, 80+). Tumor stage was categorized as American Joint Committee on Cancer
(AJCC) stage T1 (clinically inapparent) or T2 (clinically apparent, confined to prostate)
using the SEER clinical extent-of-disease information. Tumor grade was categorized as
well-differentiated (Gleason score 2–4), moderately differentiated (Gleason score 5–7), or
poorly differentiated (Gleason score 8–10) as defined by SEER.[15] Race/ethnicity was
categorized as non-Hispanic white, non-Hispanic black, Hispanic, or Asian/Pacific Islander.
[16] Socioeconomic status (SES) was measured using a neighborhood-level index that
incorporates Census data on education, income, occupation, and housing costs at the census
block-group level.[17] Each case was assigned to his neighborhood SES quintile based on
the distribution of the composite SES index across California.
The CCR collects information on the first course of treatment for prostate cancer that was
administered or initiated within four months of diagnosis. Primary treatment was
categorized as surgery, radiotherapy, ADT monotherapy, or conservative management (no
therapy within four months of diagnosis). Surgery denotes procedures such as prostatectomy
that ablate the organ; patients classified as having received surgery included those who also
received adjuvant radiation and/or ADT. Radiotherapy denotes external beam radiation and/
or brachytherapy; patients classified as having received radiotherapy included those who
received both radiotherapy and ADT. ADT monotherapy denotes initial treatment with only
hormone therapy or endocrine surgery (orchiectomy).
Statistical Analysis
Competing risks of death from prostate cancer or other causes were estimated for each of the
four primary treatment groups, stratified by age, grade, and stage at diagnosis. Cumulative
incidence functions were used to estimate the absolute risk of dying of either prostate cancer
or other causes, and global tests of the equality of estimated mortality curves across
treatment groups were performed using the cmprsk package[18,19] implemented in R (R
Foundation for Statistical Computing, Vienna, Austria). 95% confidence intervals (CI) for
10-year cumulative mortality estimates were constructed using the delta method and log-
odds transformation to obtain estimates between 0 and 1.[20] We assessed the sensitivity of
results to potential misclassification of clinical stage by comparing results in the surgery
group overall to the subset of 9,665 surgically treated men with pathologically confirmed
localized disease. All p-values were 2-sided.
RESULTS
As of May 31, 2010, 15,143 deaths had occurred among the 45,440 men diagnosed with
clinically localized prostate cancer in California during 1995–1998, and 2,720 (18%) of
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these deaths were attributed to prostate cancer (Table 1). About half of all cases had stage
T2 disease at diagnosis and 11.7% of all tumors were well differentiated. The most common
primary treatment was surgery (40.4%), followed by radiation (29.1%), conservative
management (20.8%), and ADT monotherapy (9.8%). Among surgically treated patients,
644 (3.5%) received adjuvant radiotherapy only, 2,157 (11.8%) received adjuvant ADT
only, and 250 (1.4%) received both radiotherapy and ADT within four months of diagnosis.
A substantially greater proportion of men who underwent primary radiotherapy received
adjuvant ADT (40.7%) compared with men who underwent surgery (13.1%).
Characteristics of patients in the four primary treatment groups are shown in Table 1.
Patients who initially received conservative management tended to be older (median age 73
years) at diagnosis, and to have well-differentiated and T1 disease. Surgically treated
patients were youngest (median age 64 years) at diagnosis, and least likely to have well-
differentiated tumors at diagnosis. Patients treated with radiation were intermediate to the
other treatment groups with respect to age (median 70 years) at diagnosis and tumor grade,
but were the most likely to have T2 disease at diagnosis. Patients who received ADT
monotherapy were the oldest (median age 75 years) at diagnosis, and most likely to have
poorly differentiated tumors.
Table 2 shows the sample size and proportion of the 45,440 men with clinically localized
prostate cancer that died from their disease or other causes, stratified by age at diagnosis,
tumor grade and stage. In general, men with localized prostate cancer were far more likely to
die from other causes than from their disease, except for men <60 years diagnosed with
poorly differentiated disease. As expected, the proportion of men who died from prostate
cancer generally increased with older age, higher grade, and clinically apparent disease at
diagnosis. The 10-year cumulative mortality rate among all men with localized prostate
cancer was 6.5% (95% CI, 6.2–6.7%) for prostate cancer and 27.0% (95% CI, 26.5–27.4%)
for competing causes of death. Patients with well, moderately, or poorly differentiated
disease respectively had 10-year cumulative mortality rates of 2.7% (95% CI, 2.3–3.2%),
4.3% (95% CI, 4.1–4.5%), and 15.1% (95% CI, 14.3–15.9%) for prostate cancer and 33.5%
(95% CI, 32.2–34.8%), 26.5% (95% CI, 26.0–26.9%), and 29.0% (95% CI, 28.0–30.0%) for
competing causes of death.
Figure 1 shows the estimated mortality curves for prostate cancer or competing causes of
death among patients in each of the four primary treatment groups, stratified by age, grade,
and stage at diagnosis. Prostate cancer mortality curves differed significantly across
treatment groups among men <80 years with moderately or poorly differentiated disease
(Table 3). However, no significant differences in prostate cancer mortality were found
across treatment groups for men <70 years with well-differentiated disease or ≥80 years with
moderately or poorly differentiated disease (Table 3). The small number of prostate cancer
deaths among men with well-differentiated disease and surgically treated men ≥80 years
limited the reliability of mortality estimates in these groups.
Prostate cancer mortality was highest among patients who received ADT monotherapy
(Figure 1B) across all strata, and was especially high among men <70 years diagnosed with
poorly differentiated disease. Men who received ADT monotherapy or conservative
management (Figure 1A) both experienced relatively high mortality from causes other than
their disease. Prostate cancer mortality was generally similar in men who received
conservative management or radiotherapy (Figure 1C), although men diagnosed at age ≥70
or with poorly differentiated disease who were treated with radiotherapy tended to have
lower mortality rates than those who received conservative management. Surgically treated
men (Figure 1D) had the lowest mortality from prostate cancer among men <80 years with
moderately or poorly differentiated disease. Sensitivity analyses among men with
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pathologically confirmed localized disease following radical prostatectomy with lymph node
dissection showed that prostate cancer mortality was slightly lower but similar to that for all
surgically treated men (data not shown), indicating that misclassification of clinical stage did
not have a substantial impact on the results.
DISCUSSION
Determining the optimal treatment of localized prostate cancer is a great challenge for
physicians and patients, given limited evidence to date regarding the comparative
effectiveness of treatment alternatives. In this population-based cohort of 45,440 California
men with clinically localized prostate cancer, we found that patients who were initially
treated with surgery, radiotherapy, ADT monotherapy, or conservative management differed
significantly with respect to their ten-year risk of dying from prostate cancer or competing
causes. To our knowledge, this large observational study is the first to compare mortality
estimates among men with clinically localized prostate cancer treated with surgery,
radiation, conservative management, as well as ADT monotherapy. This information
provides a framework for understanding the expected long-term outcomes of localized
prostate cancer given the initial treatment choice and practice patterns in the general
population.
Although ADT monotherapy is not recommended for localized prostate cancer,[6] it was
received by 9.8% of the men in this cohort. This proportion was slightly higher than the
estimate of 7.6% from a SEER Patterns of Care study (POC) in which treatment data from
medical records was supplemented by forms sent to physicians for men diagnosed with
localized disease in 1998.[21] We found that combined therapy with ADT was utilized by
40.7% and 13.1% of patients treated with radiotherapy and surgery, respectively. A
randomized trial of radiotherapy combined with ADT versus radiotherapy alone for
localized prostate cancer reported that combined therapy significantly decreased disease-
specific mortality.[22] In contrast, several randomized trials of neoadjuvant ADT before
surgery have not shown a survival benefit,[23,24,25] which may help explain the
substantially greater frequency of ADT use among men treated with radiotherapy versus
surgery. We found that men treated with ADT monotherapy had the highest disease-specific
mortality across all strata of age, grade, and stage at diagnosis, consistent with previous
studies including one randomized trial that did not find a survival benefit with ADT
monotherapy.[7,26,27] It is possible that men treated with ADT monotherapy have higher-
risk disease, contributing to poorer outcomes. However, in light of evidence that ADT is
adversely associated with osteoporosis,[28] cardiovascular disease and diabetes,[29,30] and
the lack of evidence of a survival benefit from ADT monotherapy, it is especially important
for patients and physicians to be aware of the long-term outcomes among men in this group
when considering treatment options.
Approximately 70% of California men with localized prostate cancer underwent attempted
curative treatment with surgery (40.4%) or radiation (29.1%). We found that men <80 years
with moderately to poorly differentiated disease treated with surgery had the lowest
mortality from prostate cancer. Patients ≥70 years initially treated with radiotherapy versus
conservative managment generally had lower disease-specific mortality, although the
differences were not significant among men ≥80 years. These findings are consistent with
evidence from randomized trials that treatment with surgery[9] or high-dose
radiotherapy[31,32,33,34,35] improves outcomes of localized prostate cancer. In subgroup
analyses from randomized trials, surgery significantly reduced overall and disease-specific
mortality only among men <65 years,[9] whereas radiation combined with ADT versus
radiation alone significantly reduced disease-specific mortality only among men ≥70 years.
[22] Thus, evidence from both clinical trials and observational studies suggests that active
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treatment with radiotherapy may be more effective in older men, whereas surgery may be
more effective in younger men.[36] Alternative explanations for the better outcomes among
actively treated men include patient selection based on life expectancy ≥10 years, absence of
comorbidities that contraindicate treatment,[6] or other unmeasured factors associated with
improved prostate cancer survival.
We found no significant differences in prostate cancer mortality across treatment groups
among men <70 with well-differentiated disease or ≥80 years with moderately or poorly
differentiated disease, suggesting that conservative management is a safe and effective
choice for these patients. The mortality estimates for California men who underwent initial
conservative management was similar to U.S. men diagnosed with localized prostate cancer
during 1992–2002 who were managed without surgery or radiation but may have received
ADT within six months of diagnosis.[37] Studies of SEER treatment data for prostate cancer
have shown that, whereas surgery and radiation are well captured,[38,39] hormonal therapy
may be underascertained by medical record abstraction compared to patient self-report.[40]
Thus, one potential limitation of the present study is that the conservative management
group may include some men who received ADT. However, the similar proportion of men
who received initial ADT monotherapy in this study compared to a SEER POC study in
1998 that supplemented registry data with physician surveys[21] suggests that the degree of
ADT underascertainment by the CCR may be relatively modest. The high mortality from
non-prostate cancer causes among men who initially received conservative management or
ADT monotherapy may reflect high comorbidity contraindicating aggressive treatment.
Greater comorbidity has been associated with higher overall mortality as well as lower
prostate-cancer-specific mortality.[41]
The main limitation of this observational study was that, without randomization, primary
treatment groups may differ systematically with respect to unmeasured characteristics such
as comorbidities that influence mortality. Thus, the data presented here are intended to
describe mortality given a patient’s initial treatment choice and practice patterns in the
general population, and should not be interpreted as a quantification of treatment effects.
Additionally, the CCR, like other SEER registries, does not have information on PSA values
at diagnosis, and Gleason 5–7 tumors were collapsed as moderately differentiated disease,
potentially obscuring survival differences in this group. The main strengths of this
observational cohort study are the large sample size, follow-up for over ten years, and
population-based setting, with capture of nearly all prostate cancer cases diagnosed in
California. Thus, the findings are robust and broadly applicable, and are not restricted to
specific clinics or age groups as is often the case for clinical trials or Medicare claims-based
studies.
This study provides population-based estimates of a man’s absolute risk of dying from
prostate cancer or other causes within ten years of his diagnosis with localized prostate
cancer depending upon his initial treatment choice and disease characteristics. These data
may help patients and physicians to better understand the expected long-term outcomes of
clinically localized prostate cancer in the context of practice patterns in the general
population. Additional studies will be needed to characterize mortality trends as practice
patterns change over time.
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Competing risk of death among men with localized prostate cancer who received primary
treatment with conservative management (A), ADT monotherapy (B), radiation therapy (C)
or surgery (D), stratified by age at diagnosis, tumor stage and grade. Prostate cancer
mortality (dark grey), non-prostate cancer mortality (light grey), survival probability (white).
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Table 1
Characteristics of California men diagnosed with clinically localized prostate cancer in 1995–1998, overall












n % n % n % n % n %
10-year survival
 Alive 30,297 (66.7) 4575 (48.5) 15412 (84.0) 8651 (65.5) 1659 (37.3)
 Died of prostate cancer 2,720 (6.0) 611 (6.5) 537 (2.9) 815 (6.2) 757 (17.0)
 Died of other causes 12,423 (27.3) 4249 (45.0) 2406 (13.1) 3737 (28.3) 2031 (45.7)
Age at diagnosis (years)
 <50 797 (1.8) 64 (0.7) 614 (3.3) 102 (0.8) 17 (0.4)
 50–59 7,005 (15.4) 654 (6.9) 4798 (26.1) 1309 (9.9) 244 (5.5)
 60–69 17,735 (39.0) 2457 (26.0) 9554 (52.1) 4784 (36.2) 940 (21.1)
 70–79 16,268 (35.8) 4329 (45.9) 3349 (18.2) 6576 (49.8) 2014 (45.3)
 80+ 3,635 (8.0) 1931 (20.5) 40 (0.2) 432 (3.3) 1232 (27.7)
Race/ethnicity
 Non-Hispanic White 34,218 (75.3) 6838 (72.5) 13881 (75.6) 10156 (76.9) 3343 (75.2)
 Non-Hispanic Black 3,931 (8.7) 922 (9.8) 1466 (8.0) 1150 (8.7) 393 (8.8)
 Hispanic 4,936 (10.9) 1106 (11.7) 2127 (11.6) 1232 (9.3) 471 (10.6)
 Asian/Pacific Islander 2,355 (5.2) 569 (6.0) 881 (4.8) 665 (5.0) 240 (5.4)
Neighborhood SES (quintile)
 1 (lowest) 5,114 (11.3) 1438 (15.2) 1738 (9.5) 1294 (9.8) 644 (14.5)
 2 7,700 (16.9) 1846 (19.6) 2869 (15.6) 2161 (16.4) 824 (18.5)
 3 9,144 (20.1) 1953 (20.7) 3461 (18.9) 2784 (21.1) 946 (21.3)
 4 10,415 (22.9) 1989 (21.1) 4324 (23.6) 3116 (23.6) 986 (22.2)
 5 (highest) 13,067 (28.8) 2209 (23.4) 5963 (32.5) 3848 (29.1) 1047 (23.5)
Gleason score, tumor grade
 2–4, well-differentiated 5,330 (11.7) 2515 (26.7) 1016 (5.5) 1423 (10.8) 376 (8.5)
 5–7, moderately differentiated 32,092 (70.6) 5961 (63.2) 13800 (75.2) 9540 (72.3) 2791 (62.8)
 8–10, poorly differentiated 8,018 (17.6) 959 (10.2) 3539 (19.3) 2240 (17.0) 1280 (28.8)
Clinical stage
 T1 21,965 (48.3) 5917 (62.7) 9309 (50.7) 4993 (37.8) 1746 (39.3)
 T2 23,475 (51.7) 3518 (37.3) 9046 (49.3) 8210 (62.2) 2701 (60.7)
Adjuvant ADT use
 No 33,213 (73.1) 15948 (86.9) 7830 (59.3)
 Yes 12,227 (26.9) 2407 (13.1) 5373 (40.7)
ADT = androgen deprivation therapy; SES = socioeconomic status.
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Table 2
Sample sizes by age and vital status as of May 2010 among California men diagnosed with clinically localized
prostate cancer in 1995–1998.











Gleason 2–4, T1 and T2
 Alive 616 (89.5) 1448 (78.1) 1242 (56.4) 112 (19.0) 3418 (64.1)
 Died of prostate cancer 9 (1.3) 39 (2.1) 66 (3.0) 30 (5.1) 144 (2.7)
 Died of other causes 63 (9.2) 366 (19.8) 893 (40.6) 446 (75.9) 1768 (33.2)
Gleason 5–7, T1
 Alive 2633 (90.8) 5036 (80.7) 2873 (57.1) 206 (17.8) 10748 (70.2)
 Died of prostate cancer 47 (1.6) 143 (2.3) 234 (4.7) 121 (10.5) 545 (3.6)
 Died of other causes 219 (7.6) 1059 (17.0) 1921 (38.2) 828 (71.7) 4027 (26.3)
Gleason 5–7, T2
 Alive 2708 (89.3) 5192 (78.0) 3511 (58.1) 215 (20.7) 11626 (69.3)
 Died of prostate cancer 67 (2.2) 247 (3.7) 376 (6.2) 123 (11.9) 813 (4.8)
 Died of other causes 257 (8.5) 1217 (18.3) 2160 (35.7) 699 (67.4) 4333 (25.8)
Gleason 8–10, T1
 Alive 397 (80.0) 862 (72.5) 574 (50.7) 57 (15.5) 1890 (59.4)
 Died of prostate cancer 58 (11.7) 103 (8.7) 161 (14.2) 93 (25.3) 415 (13.0)
 Died of other causes 41 (8.3) 224 (18.8) 397 (35.1) 217 (59.1) 879 (27.6)
Gleason 8–10, T2
 Alive 538 (78.3) 1178 (65.5) 838 (45.1) 61 (12.5) 2615 (54.1)
 Died of prostate cancer 100 (14.6) 261 (14.5) 316 (17.0) 126 (25.8) 803 (16.6)
 Died of other causes 49 (7.1) 360 (20.0) 706 (38.0) 301 (61.7) 1416 (29.3)
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